Insider Selling: Cardlytics Inc (NASDAQ:CDLX) Director Sells $3,230,000.00 in Stock

Cardlytics Inc (NASDAQ:CDLX) Director Mark A. Johnson sold 100,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $32.30, for a total transaction of $3,230,000.00.

Shares of NASDAQ CDLX opened at $34.10 on Thursday. The firm has a market cap of $808.56 million, a PE ratio of -15.93 and a beta of 1.53. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. Cardlytics Inc has a 1-year low of $9.80 and a 1-year high of $39.62. The company has a fifty day moving average price of $33.69 and a 200 day moving average price of $24.16.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.23. The firm had revenue of $48.73 million during the quarter, compared to analyst estimates of $43.77 million. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The company’s revenue for the quarter was up 37.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.21) EPS. Equities research analysts forecast that Cardlytics Inc will post -1.08 EPS for the current year.



Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Cardlytics by 94.2% during the 2nd quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock worth $23,476,000 after buying an additional 438,215 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC acquired a new position in shares of Cardlytics during the 2nd quarter worth about $10,392,000. Vanguard Group Inc. boosted its stake in shares of Cardlytics by 46.1% during the 2nd quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock worth $19,618,000 after buying an additional 238,211 shares during the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Cardlytics by 11.5% during the 1st quarter. Frontier Capital Management Co. LLC now owns 1,631,248 shares of the company’s stock worth $26,981,000 after buying an additional 168,471 shares during the last quarter. Finally, Antipodean Advisors LLC acquired a new position in shares of Cardlytics during the 2nd quarter worth about $3,698,000. 85.01% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently commented on CDLX shares. ValuEngine cut shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. William Blair initiated coverage on shares of Cardlytics in a research note on Monday, July 1st. They issued an “outperform” rating for the company. Raymond James upped their target price on shares of Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, SunTrust Banks upped their target price on shares of Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $33.29.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: What is a death cross?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.